Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

BACKGROUND: The extent to which response and survival benefits with immunotherapy-based regimens persist informs optimal first-line treatment options. We provide long-term follow-up in patients with advanced renal cell carcinoma (aRCC) receiving first-line nivolumab plus ipilimumab (NIVO+IPI) versus...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Immunother Cancer
Main Authors: Motzer, Robert J, Escudier, Bernard, McDermott, David F, Arén Frontera, Osvaldo, Melichar, Bohuslav, Powles, Thomas, Donskov, Frede, Plimack, Elizabeth R, Barthélémy, Philippe, Hammers, Hans J, George, Saby, Grünwald, Viktor, Porta, Camillo, Neiman, Victoria, Ravaud, Alain, Choueiri, Toni K, Rini, Brian I, Salman, Pamela, Kollmannsberger, Christian K, Tykodi, Scott S, Grimm, Marc-Oliver, Gurney, Howard, Leibowitz-Amit, Raya, Geertsen, Poul F, Amin, Asim, Tomita, Yoshihiko, McHenry, M Brent, Saggi, Shruti Shally, Tannir, Nizar M
Format: Artigo
Sprog:Inglês
Udgivet: BMJ Publishing Group 2021
Fag:
Clinical/Translational Cancer Immunotherapy
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7359377/
https://ncbi.nlm.nih.gov/pubmed/32661118
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000891
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker